Both in Biotechnology
Coherus Oncology vs enGene Therapeutics
Over the past year CHRS returned −45.1% and ENGN returned −73.7%; their daily moves had a correlation of 0.10.
CHRS −45.1% ENGN −73.7%Growth of $1, one year, split-adjusted
| Metric | CHRS | ENGN |
|---|---|---|
| Price | $0.8502 | $1.72 |
| Market cap | $131.4M | $115.3M |
| Today | +5.54% | +6.17% |
| 1 month | −17.5% | −4.4% |
| 6 months | −51.4% | −80.6% |
| Year to date | −40.1% | −81.0% |
| 1 year | −46.9% | −75.1% |
| Revenue growth (YoY) | +39.5% | — |
| Gross margin | 70.4% | — |
| Net margin | −144.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 2.6× | — |
| Net cash | $68.1M | $241.0M |
| Dividend yield | — | — |
| Volatility (60d) | 95.4% | 58.2% |
| Short % of float | 9.5% | 3.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).